A new study published today demonstrates that a technology developed at the University of Central Florida could serve as a more reliable clinically-based model of amyotrophic lateral sclerosis (ALS) and a better screening tool for novel therapies than currently use preclinical models.
- ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
- No benefit for post-operative radiotherapy in non-small-cell lung cancer
- First new drug in years reduces recurrence in high risk HR+ early breast cancer
- New first-line treatment option for metastatic kidney cancer
- UC study sheds light on cancer treatment, COVID-19